Portal de investigación
- Inicio
- Proyectos y Estudios
- CRÓNICA-UC: EVALUACIÓN DE LA CAPACIDAD DIAGNÓSTICA DEL CUESTIONARIO DE WALMSLEY UTILIZADO EN UNA APLICACIÓN ONLINE (CUMPLIMENTADO POR EL PROPIO PACIENTE "VÍA WEB") EN COMPARACIÓN CON EL MISMO CUESTIONARIO APLICADO POR EL MÉDICO EN SU CONSULTA EN PACIENTES CON COLITIS ULCEROSA.
CRÓNICA-UC: EVALUACIÓN DE LA CAPACIDAD DIAGNÓSTICA DEL CUESTIONARIO DE WALMSLEY UTILIZADO EN UNA APLICACIÓN ONLINE (CUMPLIMENTADO POR EL PROPIO PACIENTE "VÍA WEB") EN COMPARACIÓN CON EL MISMO CUESTIONARIO APLICADO POR EL MÉDICO EN SU CONSULTA EN PACIENTES CON COLITIS ULCEROSA.
Datos básicos
- Código:
- MSD-COL-2012-01
- Protocolo:
- MSD-COL-2012-01
- EUDRACT:
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Peripheral arterial thromboembolism in Crohn's disease].
Ferrer I; (...); Nos P
Abstract of Published Item. 10.1016/j.gastrohep.2012.04.011. 2013
1-Butanol absorption in poly(styrene-divinylbenzene) ion exchange resins for catalysis
Pérez-Maciá MA; (...); Aleman C
Article. 10.1039/c5sm02168e. 2015
A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis
Julià A; (...); Marsal S
Article. 10.1093/hmg/ddu398. 2014
A genome-wide association study identifies DSE-FAM26F as a risk locus for ulcerative colitis
Domenech, E.; (...); Gisbert, J. P.
Article. 10.1016/S1873-9946(14)60784-4. 2014
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300.
Julià A; (...); Marsal S
Article. 10.1136/gutjnl-2012-302865. 2013
A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.
Cerrillo E; (...); Beltrán B
Article. 10.1093/ibd/izz053. 2019
A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial
Meeting Abstract. 2017
A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.2196/11602. 2018
A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): Results of a randomised controlled clinical trial
Meeting Abstract. 2018
A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial
Aguas, Mariam; (...); Nos, Pilar
Article. 10.2196/resprot.9639. 2018
Accuracy of magnetic resonance enterography in the preoperative assessment of patients with Crohn's disease of the small bowel
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1111/codi.13613. 2017
Acute cholecystitis after colonoscopy: A rare complication.
Ladrón Abia P; (...); Del Hoyo F
Article. 10.1016/j.rgmxen.2022.05.007. 2022
Acute cholecystitis after colonoscopy: A rarecomplication
Abia, P. Ladron; (...); Del Hoyo, F.
Letter. 10.1016/j.rgmx.2022.03.003. 2022
Acute myocardial infarction in a patient with a recent diagnosis of Crohn's disease
Navarro, B; (...); Iborra, M
Editorial Material. 10.1016/j.gastrohep.2018.05.008. 2019
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
Cañete F; (...); ENEIDA registry by GETECCU
Article. 10.1093/ibd/izz084. 2019
-
-
PlumX Metrics
- Citations
- Citation Indexes: 36
- Policy Citations: 4
- Captures
- Readers: 72
- Mentions
- News Mentions: 1
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial
Lopez-Sanroman, A; (...); Spanish GETECCU Grp APPRECIA Study
Article. 10.1093/ecco-jcc/jjx051. 2017
Adaptation of TECCU App Based on Patients ' Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups
Del Hoyo, J; (...); Aguas, M
Article. 10.3390/ijerph17061871. 2020
Adaptation of TECCU App based on patients' perceptions for telemonitoring inflammatory bowel disease: A qualitative study using focus groups
Francisco, JD; (...); Aguas, M
Meeting Abstract. 2020
Adherence to diagnostic and treatment recommendations for the management of acute severe ulcerative colitis: a prospective and multinational study
Rodriguez-Lago, I.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU
Ballester Ferre, M. P.; (...); Minguez, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.727. 2021
Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines
Beltran, B; (...); Nos, P
Article. 10.1002/jca.21552. 2018
Alpha-defensins (alpha-Defs) in Crohn's disease: decrease of ileal alpha-Def 5 via permanent methylation and increase in plasma alpha-Def 1-3 concentrations offering biomarker utility
Cerrillo, E; (...); Beltran, B
Article. 10.1111/cei.13085. 2018
Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study)
Bastida, G; (...); Barreiro-de Acosta, M
Meeting Abstract. 10.1093/ecco-jcc/jjy222.251. 2019
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Canete, F; (...); Domenech, E
Article. 10.14309/ctg.0000000000000218. 2020
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Chaparro, M; (...); EXIT Study Grp GETECCU
Article. 10.1177/1756284819874202. 2019
Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers.
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.3748/wjg.v29.i7.1139. 2023
Assessing an improved protocol for plasma microRNA extraction.
Moret I; (...); Beltrán B
Article. 10.1371/journal.pone.0082753. 2013
Association between Chronotype, Physical Activity and Sedentary Behaviour: A Systematic Review
Sempere-Rubio, Nuria, Aguas, Mariam, Faubel, Raquel
Article. 10.3390/ijerph19159646. 2022
Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study
Panes, Julian; (...); Marin-Jimenez, Ignacio
Article. 10.1111/jgh.13795. 2017
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Taxonera, Carlos; (...); Alba, Cristina
Article. 10.1111/apt.16964. 2022
Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis
Taxonera Samso, C.; (...); Alba, C.
Meeting Abstract. 2022
Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease
SÁEZ, E.; (...); BELTRÁN, B.
Article. 10.3390/nu11051062. 2019
Biomarkers response to anti-TNF treatment in Crohn's disease through the intestinal microbiota
Sanchis, L; (...); Cortes, X
Meeting Abstract. 2020
Catalase inhibition can modulate the ability of peripheral blood T cells to undergo apoptosis in Crohn's disease.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.1093/cei/uxad134. 2024
Certification of integral care IBD Units: Evaluation of a certification program (CUE)
Barreiro-de Acosta, M; (...); GETECCU
Meeting Abstract. 2020
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat, Margalida; (...); Domenech, Eugeni
Article. 10.1177/17562848231221713. 2024
Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations.
Ricart E; (...); González-Lama Y
Article. 10.1093/crocol/otae055. 2024
Clinical characteristics and management of Crohn's disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study
Domenech, E; (...); Julia, B
Meeting Abstract. 2018
Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Spanish nationwide study based on the ENEIDA registry
Guerra, I; (...); Gisbert, JP
Meeting Abstract. 2018
Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study.
Guerra I; (...); Gisbert JP
Article. 10.1093/ecco-jcc/jjz094. 2019
Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry
Madero Velazquez, L.; (...); Gutierrez-Casbas, A.
Meeting Abstract. 2024
Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry
Gonzalez Munoza, C.; (...); Garcia-Planella, E.
Meeting Abstract. 2022
Colorectal cancer diagnosis in patients with inflammatory bowel disease in Spain: A room for improvement
Saldana, R; (...); Mateu, PN
Meeting Abstract. 2020
Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-alpha drug failure
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1016/j.dld.2018.01.124. 2018
Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensus
Gonzalez Lama, Y.; (...); Munoz, F.
Meeting Abstract. 2023
Correlation between adalimumab serum levels and remission after the induction phase in Crohn's Disease patients
Chaparro, M.; (...); Gisbert, J. P.
Article. 2015
Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease
Pous-Serrano, Salvador; (...); Nos, Pilar
Article. 10.1016/j.jss.2017.02.064. 2017
Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658].
Barreiro-de Acosta M; (...); Nos P
Correction. 10.1016/j.gastrohep.2021.02.001. 2021
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab242. 2021
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
Aguas Peris, M.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0428. 2025
Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
Del Hoyo J, Aguas M
Letter. 10.1016/j.cgh.2020.06.016. 2021
Crohn's disease and self-monitoring through a mobile App: The Medicrohn study
Echarri, A; (...); Nos, P
Meeting Abstract. 2018
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group
Fernández-Bañares F; (...); Gisbert JP
Article. 10.1111/apt.13477. 2016
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 55
- Policy Citations: 1
- Captures
- Readers: 129
- Mentions
- References: 1
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.1016/j.gastrohep.2021.08.006. 2021
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Del Hoyo Francisco, J.; (...); Aguas, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.758. 2021
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; (...); Domènech E
Article. 10.1111/jgh.15084. 2020
Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; (...); Herrerías-Gutiérrez JM
Article. 10.1007/s10620-013-2762-2. 2013
Characteristics of drug-induced lupus 2 degrees to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
Manosa, M; (...); Domenech, E
Meeting Abstract. 2017
Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study
Cabre, E; (...); Domenech, E
Article. 10.1016/j.dld.2018.12.004. 2019
Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn's disease
Ladron Abia, P.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.537. 2021
Decreased Esophageal Sensitivity to Acid in Morbidly Obese Patients: A Cause for Concern?
Ortiz, V; (...); Garrigues, V
Article. 10.5009/gnl16081. 2017
Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources
Sempere Robles, L.; (...); Ruiz, M. T.
Article. 2022
Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown
Sempere Robles, L.; (...); van-der Hofstadt, C.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.270. 2021
Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease
Iborra, M; (...); Beltran, B
Article. 10.1159/000493726. 2019
Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn's disease
Mateos, B; (...); Beltran, B
Meeting Abstract. 10.1093/ecco-jcc/jjy222.725. 2019
Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN study
Iborra, M; (...); Julia, B
Meeting Abstract. 2017
Disease severity in familial cases of IBD
Andreu M; (...); Panés J
Article. 10.1016/j.crohns.2013.08.010. 2014
DNA methylation signatures associated with pathogenesis Crohn's disease-related genes
Tatay, IM; (...); Beltran, B
Meeting Abstract. 2019
Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2024
Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2023
Does smoking influence Crohn's disease in the biologic era? The TABACROHN study.
Nunes T; (...); Sans M
Article. 10.1002/ibd.22959. 2013
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Taxonera, C; (...); Alba, C
Article. 10.1080/03007995.2019.1579557. 2019
Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study
Frasson, M.; (...); Pellino, G.
Meeting Abstract. 2023
Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
Rodríguez-Lago I; (...); Gisbert JP
Article. 10.1177/2050640620947579. 2020
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Taxonera, C; (...); SEGURTB study gro GETECCU
Article. 10.1093/ecco-jcc/jjx022. 2017
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply
Editorial Material. 10.1111/apt.15447. 2019
Efectiveness And Safety Of Ustekinumab In Elderly Patients With Crohn's Disease: Real World Evidence From The Eneida Registry.
Casas-Deza, Diego; (...); Garcia-Lopez, Y Santiago
Article. 10.1093/ecco-jcc/jjac108. 2022
Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.
Guardiola Capon, J.; (...); Rodriguez-Moranta, F.
Meeting Abstract. 2024
Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Garcia, M. J.; (...); Chaparro, M.
Meeting Abstract. 2023
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
Garcia, Maria Jose; (...); Chaparro, Maria
Article. 10.1111/apt.17938. 2024
Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry
Mesonero, F; (...); Lopez-Sanroman, A
Article. 10.1111/apt.16315. 2021
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Casanova MJ; (...); Gisbert JP
Article. 10.1093/ibd/izz192. 2020
Effectiveness and Safety of the Switch from Remicade (R) to CT-P13 in Patients with Inflammatory Bowel Disease
Chaparro, M; (...); Gisbert, JP
Article. 10.1093/ecco-jcc/jjz070. 2019
Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
Teresa VD; (...); Federico, Arguelles-Arias
Article. 10.1177/17562848231153560. 2023
Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
Chaparro, M; (...); Esteve M
Meeting Abstract. 10.1093/ecco-jcc/jjz203.563. 2020
Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
Chaparro, Maria; (...); Lázaro Pérez-Calle, José
Article. 10.1093/ecco-jcc/jjab070. 2021
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Article. 10.1007/s00535-016-1274-1. 2017
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017)
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Correction. 10.1007/s00535-016-1293-y. 2017
Effectiveness of Upadacitinib in Patients with Baseline Active Extraintestinal Manifestations and Inflammatory Bowel Disease. A multicenter retrospective study
Fuentes-Valenzuela, E.; (...); Barrio, J.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1180. 2025
Effectiveness of vedolizumab (VDZ) for the induction of remission in inflammatory bowel disease (IBD): Results from the Spanish Eneida Registry
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2018
Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: A randomised controlled trial
Meeting Abstract. 2018
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial.
Ginard, Daniel; (...); Sans, Miquel
Article. 10.1159/000540792. 2024
Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn's disease. Data from clinical practice from the eneida registry
Ciria, MM; (...); Domenech, E
Meeting Abstract. 2020
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: PRACTICROHN study
Barreiro-de Acosta, M; (...); Domenech, E
Meeting Abstract. 2018
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study.
Barreiro-De Acosta, M; (...); Julia, B
Article. 10.1080/17474124.2019.1626717. 2019
-
-
PlumX Metrics
- Citations
- Policy Citations: 2
- Citation Indexes: 4
- Captures
- Readers: 39
- Mentions
- News Mentions: 1
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819847034. 2019
Epidemiological risk factors in microscopic colitis: a prospective case-control study.
Fernández-Bañares F; (...); Viver JM
Article. 10.1002/ibd.23009. 2013
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Grp
Meeting Abstract. 10.1093/ecco-jcc/jjy222.914. 2019
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2020
Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Grp
Meeting Abstract. 2018
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity.
Guijarro LG; (...); Hernández-Breijo B
Article. 10.3390/biomedicines10030727. 2022
Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment
Sanchis-Artero, L; (...); Cortes-Rizo, X
Article. 10.1038/s41598-021-88823-2. 2021
Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Article. 10.1016/j.gastrohep.2023.12.001. 2024
Evolution of the emotional impact in patients with early inflammatory bowel disease during and after Covid-19 lockdown.
Sempere L; (...); Hofstadt CV
Article. 10.1016/j.gastrohep.2021.03.004. 2021
Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry
Chaparro, M; (...); Gisbert, JP
Article. 10.1038/ajg.2017.96. 2017
-
-
PlumX Metrics
- Citations
- Citation Indexes: 24
- Policy Citations: 1
- Captures
- Readers: 85
- Mentions
- News Mentions: 1
Extracolonic neoplasias in Inflammatory Bowel Disease patients: Data from the GETECCU ENEIDA registry
Chaparro, M.; (...); Gisbert, J. P.
Article. 2015
Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.
Algaba A; (...); Bermejo F
Article. 10.1007/s10620-020-06424-x. 2020
Faecal calprotectin and plasma cytokines in the prediction of early postoperative Crohn's disease recurrence
Cerrillo, E; (...); Beltran, B
Meeting Abstract. 2018
Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project.
Orejudo, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score
Cerrillo E; (...); Nos P
Article. 10.1097/MIB.0000000000000404. 2015
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia.
Huguet JM; (...); Paredes JM
Article. 10.3390/jcm11102786. 2022
Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
Ladrón Abia P; (...); Bastida Paz G
Letter. 10.1016/j.gastrohep.2020.07.020. 2021
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819867848. 2019
Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study.
Sempere L; (...); Ruiz-Cantero MT
Article. 10.1093/ibd/izad001. 2023
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.
Aterido, A; (...); Julia, A
Article. 10.1038/s41397-019-0090-4. 2019
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Granulocyte-monocyte apheresis combination therapy after loss of response to anti-TNF drugs
Rodriguez-Lago, I; (...); Cabriada, JL
Meeting Abstract. 2018
Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.
Del Hoyo J; (...); Aguilera V
Editorial Material. 10.1111/jgh.15174. 2020
High smoking cessation rate in Crohn's disease patients after physician advice--the TABACROHN Study.
Nunes T; (...); Sans M
Article. 10.1016/j.crohns.2012.04.011. 2013
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
Calafat M; (...); Domènech E
Article. 10.14309/ajg.0000000000002965. 2024
Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.
Moret-Tatay I; (...); Beltrán B
Article. 10.14309/ctg.0000000000000083. 2019
Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study
Alonso A; (...); Gisbert JP
Article. 10.1053/j.gastro.2014.12.030. 2015
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease.
Iborra M; (...); Danese S
Article. 10.1111/cei.12104. 2013
Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study
de Paredes, AGG; (...); Lopez-Sanroman, A
Article. 10.1016/j.pan.2020.02.007. 2020
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
Giordano, Antonio; (...); ENEIDA project of GETECCU
Article. 10.14309/ajg.0000000000003207. 2025
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.
Gutiérrez A; (...); Francés R
Article. 10.3389/fmed.2022.823900. 2022
Immunoepigenetic Regulation of Inflammatory Bowel Disease: Current Insights into Novel Epigenetic Modulations of the Systemic Immune Response.
Bastida, Guillermo; (...); Moret-Tatay, Ines
Article. 10.3390/genes14030554. 2023
Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Review. 10.1007/s10620-017-4577-z. 2017
Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review.
Quesada-Simo, A.; (...); Gil-Perotin, S.
Article. 10.3389/fphar.2023.1186016. 2023
Impact of comorbidities on anti-TNF alpha response and relapse in patients with inflammatory bowel disease: the VERNE study
Marin-Jimenez, I; (...); Barreiro-de Acosta, M
Article. 10.1136/bmjgast-2019-000351. 2020
Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study
Marin-Jimenez, I; (...); Barreiro-de Acosta, M
Meeting Abstract. 10.1093/ecco-jcc/jjy222.433. 2019
Impact of current smoking on the clinical course of microscopic colitis.
Fernández-Bañares F; (...); RECOMINA Project, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulce
Article. 10.1097/MIB.0b013e318281f3cc. 2013
Impact of Smoking Cessation on the Clinical Course of Crohn's Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study
Nunes, T; (...); Sans, M
Article. 10.1038/ajg.2015.401. 2016
Impact of telemonitoring on the management of Inflammatory Bowel Disease in Spain: a multicenter TECCU clinical trial
Peris, M. Aguas; (...); Nos, P.
Meeting Abstract. 2023
Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?
Del Hoyo, J, Aguas, M
Editorial Material. 10.1016/j.gastrohep.2020.05.002. 2020
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study
Domènech E; (...); Barreiro-de Acosta M
Article. 10.1097/MIB.0000000000001180. 2017
Incidence and risk factors of infection in patients with inflammatory bowel disease: longitudinal prospective INFEII registry of GETECCU
Zabana, Y.; (...); Esteve, M.
Meeting Abstract. 2024
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
Chaparro, Maria; (...); Gisbert, Javier P.
Article. 10.3390/jcm10132885. 2021
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 45
- Policy Citations: 7
- Captures
- Readers: 224
- Mentions
- Blog Mentions: 1
- News Mentions: 1
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study
Guerra, I; (...); Spanish GETECCU Grp
Article. 10.1097/MIB.0000000000000757. 2016
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 74
- Policy Citations: 3
- Clinical Citations: 1
- Captures
- Readers: 150
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Calafat, M; (...); ENEIDA Registry GETECCU
Article. 10.1111/apt.15458. 2019
-
-
PlumX Metrics
- Citations
- Citation Indexes: 42
- Policy Citations: 3
- Captures
- Readers: 52
- Mentions
- News Mentions: 4
INFLAMMATORY BOWEL DISEASE Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study
Marin-Jimenez, I; (...); Panes, J
Article. 10.1038/ajg.2015.403. 2016
Inflammatory bowel disease in patients over the age of 70y. Does the disease duration influence its behavior?
Huguet, JM; (...); Paredes, JM
Article. 10.1080/00365521.2018.1501603. 2018
Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
Barreiro-de Acosta, M; (...); Nos, P
Article. 10.1002/ueg2.12105. 2021
Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
Gonzalez Vivo, M.; (...); Marquez, L.
Meeting Abstract. 2022
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis
Taxonera C; (...); Fernández-Blanco I
Article. 10.1007/s10620-015-3735-4. 2015
Infliximab serum levels do not predict remission after the induction phase in Crohn's Disease patients
Chaparro, M.; (...); Gisbert, J. P.
Article. 2015
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.
Gonzalez-Munoza, Carlos; (...); Domenech, Eugeni
Article. 10.1093/postmj/qgae076. 2024
Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients
Lopez-Munoz, P; (...); Iborra, M
Article. 10.3390/nu11051059. 2019
Information resources used by patients with inflammatory bowel disease: Satisfaction, expectations and information gaps
Catalán-Serra I; (...); Hinojosa J
Article. 10.1016/j.gastrohep.2014.09.003. 2015
Intestinal tuberculosis simulating Crohn's disease: Differential diagnosis.
Garcia-Morales, N; (...); Iborra, M
Letter. 10.1016/j.gastrohep.2018.01.005. 2019
Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Chetwood, John David; (...); Leong, Rupert W
Article. 10.1093/ecco-jcc/jjae059. 2024
Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
Pérez de Arce E; (...); Nos P
Article. 10.1016/j.gastrohep.2021.02.022. 2021
Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
Calafat, M; (...); ENEIDA Registry GETECCU
Meeting Abstract. 10.1093/ecco-jcc/jjy222.548. 2019
Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Leishmania infection in patients with inflammatory bowel disease: Case series and literature review.
Gimeno-Pitarch L, Almela P, Nos P
Article. 10.1016/j.gastrohep.2023.04.001. 2024
Letter to the Editor on The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.
Gutierrez-Ontalvilla P; (...); Iborra M
Article. 10.1007/s00266-022-02960-1. 2022
Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab
Letter. 10.1111/apt.13433. 2016
Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2018
Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study
Ordás I; (...); Esteve M
Article. 10.1038/ajg.2017.180. 2017
Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn's Disease. Data from the ENEIDA registry
Pinero, G. S.; (...); Domenech, E.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0794. 2025
Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
Bastida, G; (...); Lobaton, T
Meeting Abstract. 2017
Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
Acosta MB; (...); Rodríguez-Lago I
Article. 10.14309/ajg.0000000000002152. 2023
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 12
- Policy Citations: 3
- Captures
- Readers: 19
- Mentions
- News Mentions: 2
Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
Gargallo-Puyuelo, C.; (...); Gomollon, F.
Meeting Abstract. 2023
Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis.
Iborra M, Alvarez-Sotomayor D, Nos P
Article. 10.2147/CEG.S34715. 2014
Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
Chaparro, M; (...); Gisbert, JP
Article. 10.1038/ajg.2017.501. 2018
Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study
Iborra, M; (...); Domenech, E
Article. 10.1093/gastro/goz029. 2019
Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey
Rodriguez-Lago, I; (...); Gisbert, JP
Article. 10.1016/j.gastrohep.2018.09.002. 2019
Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
Pérez-Brocal V; (...); Moya A
Article. 10.1097/MIB.0000000000000549. 2015
-
-
PlumX Metrics
- Citations
- Citation Indexes: 72
- Policy Citations: 1
- Captures
- Readers: 119
- Mentions
- News Mentions: 1
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Article. 10.1002/jca.22101. 2023
Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain.
Calvet X; (...); Barreiro-de Acosta M
Article. 10.1093/ecco-jcc/jjac068. 2022
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
Zabana Y; (...); Esteve M
Article. 10.3390/jcm11020421. 2022
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Ferreiro-Iglesias, Rocio; (...); Barreiro-de Acosta, Manuel
Article. 10.1111/apt.18133. 2024
Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
Article. 10.1016/j.giec.2016.06.005. 2016
Novel biomarkers associated with inflammatory bowel disease
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
García-Bosch O; (...); Panés J
Article. 10.1016/j.crohns.2012.10.004. 2013
Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world
Minguez, A.; (...); Bastida, G.
Meeting Abstract. 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
Minguez, Alejandro; (...); Bastida, Guillermo
Article. 10.1016/j.gastrohep.2024.502253. 2024
Oral locally active steroids in inflammatory bowel disease.
Nunes T; (...); Sans M
Article. 10.1016/j.crohns.2012.06.010. 2013
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease
Taxonera, C; (...); Fernandez-Blanco, I
Article. 10.1093/ecco-jcc/jjw016. 2016
Oxidative stress in Crohn's disease
Moret I; (...); Beltrán B
Article. 10.1016/j.gastrohep.2013.01.008. 2014
Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics
Alemany-Cosme, E; (...); Beltran, B
Review. 10.3390/antiox10010064. 2021
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.
Riestra S; (...); Domènech E
Article. 10.3390/jcm11133915. 2022
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU.
Casanova, Maria Jose; (...); Gisbert, Javier P
Article. 10.1016/j.dld.2024.05.009. 2024
Personalised therapy in inflammatory bowel disease
Calderón P; (...); Quera R
Article. 10.1016/j.gastrohep.2023.12.006. 2024
Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study
Manosa, M; (...); Geteccu
Article. 10.1111/apt.14494. 2018
Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database
Cabré E; (...); Domènech E
Article. 10.1016/j.crohns.2013.12.005. 2014
Phenotypic characteristics and use of therapeutic resources in elderly-onset inflammatory bowel disease: A multicentre, case control study
Manosa, M.; (...); Domenech, E.
Article. 10.1016/S1873-9946(14)60726-1. 2014
Plasma Oncostatin M, TNF-a, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
Mateos B; (...); Beltrán B
Article. 10.1159/000508069. 2020
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease.
Calvo Moya M; (...); Gutiérrez Casbas A
Article. 10.1016/j.gastrohep.2023.12.013. 2024
Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs-Current Evidences and Further Aspects to Unravel
Moret-Tatay I; (...); Beltrán B
Review. 10.1155/2016/2325162. 2016
Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study
Ibanez-Sanz, Gemma; (...); Moreno, Victor
Article. 10.1038/s41598-018-20349-6. 2018
Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Prevalence, features and outcomes of splachnic vein thrombosis in inflammatory bowel disease. A nationwide, retrospective study from the ENEIDA registry
Masnou, H; (...); Eneida-GETECCU Registry
Meeting Abstract. 2020
Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
D'Haens, G.; (...); Laharie, D.
Meeting Abstract. 2023
Primary prevention of post-operative recurrence of Crohn's disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
Canete, F; (...); Domenech, E
Meeting Abstract. 2018
Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease
Soleto, I.; (...); Chaparro, M.
Meeting Abstract. 2023
Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery
Baldan-Martin, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
Sanz Segura, Patricia; (...); Garcia-Lopez, Santiago
Article. 10.1016/j.dld.2024.05.021. 2024
Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients.
Bernabeu P; (...); Sempere L
Article. 10.3389/fpsyg.2024.1334308. 2024
Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD
Bernabeu, P.; (...); Sempere, L.
Article. 2022
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain
Hernandez Camba, A.; (...); Barreiro, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.312. 2021
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
Hernandez Camba, Alejandro; (...); Barreiro-de Acosta, Manuel
Article. 10.1016/j.gastrohep.2021.08.007. 2021
-
-
-
PlumX Metrics
- Citations
- Policy Citations: 3
- Citation Indexes: 4
- Captures
- Readers: 53
- Mentions
- News Mentions: 2
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Taxonera, C; (...); Nos, P
Article. 10.1016/j.dld.2019.01.002. 2019
Quantification of the concentration of antibodies against Infliximab in human serum using a pure antibody as calibrator
Hernandez-Breijo, B.; (...); Guijarro, L.
Article. 2015
Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis
Llao, J.; (...); Moral, E. Domenech
Meeting Abstract. 2023
Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2023
Real life effectiveness of Adalimumab for the treatment of ulcerative colitis: comparison between anti-TNF-naive and non-naive patients. Results from the Spanish ENEIDA Registry.
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2015
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
Article. 10.1038/s41598-020-73577-0. 2020
Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients
Meeting Abstract. 10.1093/ecco-jcc/jjy222.683. 2019
Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease.
Huguet, JM; (...); Paredes, JM
Article. 10.12998/wjcc.v9.i36.11285. 2021
Real-world effectiveness of vedolizumab in managing refractory pouchitis: a multicenter study on intravenous to subcutaneous transition
Gimeno-Pitarch, L.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1018. 2025
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Article. 10.1111/apt.15958. 2020
-
-
PlumX Metrics
- Citations
- Citation Indexes: 49
- Policy Citations: 1
- Captures
- Readers: 78
- Mentions
- News Mentions: 1
Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2020
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
Iborra, Marisa; (...); Nos, Pilar
Article. 10.1080/00365521.2023.2278427. 2023
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
Barreiro-de Acosta, M.; (...); Ferreiro-Iglesias, R.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0783. 2025
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry
Iborra, M; (...); Chaparro, M
Article. 10.1111/apt.15371. 2019
Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry
Meeting Abstract. 10.1093/ecco-jcc/jjy222.629. 2019
Real-world subcutaneous infliximab for inflammatory bowel disease: A systematic review and meta-analysis
Chetwood, J.; (...); Leong, R.
Meeting Abstract. 2023
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.
Hernandez-Camba, A.; (...); GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)
Article. 10.1016/j.dld.2021.10.002. 2021
Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis
Gonzalez-Lama, Y; (...); Gomollon, F
Article. 10.1016/j.gastrohep.2020.01.005. 2020
Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.
Boscá MM; (...); Hinojosa J
Review. 10.1016/j.gastrohep.2019.09.012. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients
Barreiro-de Acosta, M; (...); Gisbert, JP
Review. 10.1016/j.gastrohep.2017.10.003. 2018
-
-
PlumX Metrics
- Citations
- Citation Indexes: 28
- Policy Citations: 1
- Captures
- Readers: 151
- Mentions
- News Mentions: 1
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis.
Barreiro-de Acosta M; (...); Nos P
Editorial Material. 10.1016/j.gastrohep.2019.08.001. 2019
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Barreiro-de Acosta M; (...); Nos P
Article. 10.1016/j.gastrohep.2020.04.004. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease
Domènech E; (...); Mañosa M
Review. 10.1016/j.gastrohep.2017.05.005. 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of tiopurines in inflammatory bowel disease
Berrnejo, F; (...); Lopez-Sanroman, A
Review. 10.1016/j.gastrohep.2017.11.007. 2018
-
-
PlumX Metrics
- Citations
- Policy Citations: 1
- Citation Indexes: 41
- Captures
- Readers: 154
- Mentions
- References: 1
Recommendations of the Valencian Society of Digestive Pathology for the use of telemedicine and non-contact consultations.
Jover, Rodrigo; (...); Nos, Pilar
Article. 10.1016/j.gastrohep.2021.04.009. 2022
Regression of a giant pseudopolyp in a patient with colonic Crohn's disease after therapy with infliximab.
Sánchez Melgarejo JF; (...); Nos P
Article. 10.17235/reed.2019.6252/2019. 2019
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab015. 2021
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved.
Guijarro, Luis G.; (...); On Behalf Of The Predicrohn Study Group From Geteccu
Article. 10.1016/j.biopha.2021.112239. 2021
Relevance of Clinical Cases.
Balaguer, Francesc; (...); Saez Gonzalez, Esteban
Editorial Material. 10.1016/j.gastrohep.2022.02.001. 2022
Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.
Pous S; (...); Nos P
Article. 10.1016/j.gastrohep.2019.11.010. 2020
Reviewing the therapeutic role of budesonide in Crohn's disease
Lopez-Sanroman, A; (...); Domenech, E
Review. 10.1016/j.gastrohep.2018.05.013. 2018
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Cañas-Ventura A; (...); Andreu M
Article. 10.1016/j.crohns.2014.03.014. 2014
Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
Calafat M; (...); ENEIDA Study Group of GETECCU
Article. 10.1093/ecco-jcc/jjab213. 2021
Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 10.1093/ecco-jcc/jjy222.561. 2019
Risk of postoperative morbidity in patients having bowel resection for colonic Crohn's disease
Iesalnieks I; (...); El-Hussuna A
Article. 10.1007/s10151-018-1904-0. 2018
Role of Interleukin-8 in Predicting Long-Term Response to Vedolizumab in Ulcerative Colitis Patients
Minguez, A.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1111. 2025
Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Chaparro M; (...); Gisbert JP
Article. 10.1097/MIB.0b013e318281f28f. 2013
-
-
PlumX Metrics
- Citations
- Citation Indexes: 244
- Policy Citations: 1
- Clinical Citations: 2
- Captures
- Readers: 193
Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-alpha Treatment for Crohn's Disease
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1038/s41395-018-0420-1. 2019
Secukinumab-induced ulcerative colitis: opening Pandora's box of immunity
Fernandez-de La Varg, M; (...); Paz, GB
Letter. 10.1016/j.gastrohep.2019.12.004. 2020
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
Taxonera, C; (...); CONVERT Study Grp GETECCU
Article. 10.1093/ecco-jcc/jjy104. 2018
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory Bowel Disease Patients
Aldars-Garcia, Laila; (...); Chaparro, Maria
Article. 10.1093/ibd/izad154. 2024
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
Bosca-Watts, MM; (...); Paredes, JM
Article. 10.3748/wjg.v22.i47.10432. 2016
Short-term real-world effectiveness and safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: GRACE Study
Rodriguez-Lago, I.; (...); Cabriada, J. L.
Meeting Abstract. 2024
Should professionals provide their patients with digital health training resources?
Piudo, AE; (...); Marcos, NM
Meeting Abstract. 2020
Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
Mínguez Sabater A; (...); Bastida G
Article. 10.1016/j.gastrohep.2020.09.003. 2022
Small intestinal bacterial overgrowth in inactive Crohn's disease: Influence of thiopurine and biological treatment
Sánchez-Montes C; (...); Nos P
Article. 10.3748/wjg.v20.i38.13999. 2014
Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era.
Nunes T; (...); Panés J
Article. 10.1111/apt.12440. 2013
Specific plasma micro-RNA profiles for prediction of recurrence in Crohn's disease in pre-surgery and established recurrence scenarios
Moret, I; (...); Beltran, B
Meeting Abstract. 2020
Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.14309/ctg.0000000000000416. 2021
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review
Puig, Maria; (...); Domenech, Eugeni
Review. 10.3390/jcm12237366. 2023
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab
Hernandez-Breijo, B; (...); Guijarro, LG
Article. 10.1016/j.bcp.2016.019. 2016
Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factors
Meeting Abstract. 2018
Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
Perez-Brocal, Vicente; (...); Moya, Andres
Article. 10.1038/ctg.2013.9. 2013
Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2024
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
Article. 10.1093/ecco-jcc/jjae127. 2024
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.
Article. 10.3390/nu13061770. 2021
Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
Chaparro, M.; (...); ECCO CONFER Taskforce
Meeting Abstract. 2022
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]
Chaparro, Maria; (...); Julsgaard, Mette
Article. 10.1093/ecco-jcc/jjac050. 2022
Surgical and hospital admission in adults newly diagnosed with inflammatory bowel disease (IBD) in the biological era in Spain: Results of the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Group
Meeting Abstract. 2018
Survey of adherence to treatment in inflammatory bowel disease. ENADEII study.
Alonso-Abreu I; (...); Quintero-Carrión E
Article. 10.1016/j.gastrohep.2019.10.007. 2020
Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
Abreu, IA; (...); GETECCU
Meeting Abstract. 2019
Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU
Gros, B.; (...); Iglesias-Flores, E.
Meeting Abstract. 2024
Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry.
Calafat M; (...); Domènech E
Article. 10.1093/ecco-jcc/jjaa055. 2020
Switching to standard-dose subcutaneous vedolizumab increases the percentage of patients in biochemical remission even in those intensified with intravenous vedolizumab: one year results of a Spanish multicentre observational study
Andres Pascual, L.; (...); Sicilia, B.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1000. 2025
Takayasu's arteritis associated with Crohn's disease.
Tung Chen Y; (...); Nos Mateu P
Article. 10.1016/j.rce.2014.01.012. 2014
Telemedicine in Inflammatory Bowel Disease: Opportunities and Approaches
Aguas Peris M; (...); Nos P
Article. 10.1097/MIB.0000000000000241. 2015
Telemedicine in Inflammatory Bowel Disease: Opportunity Ahead
Letter. 10.1097/MIB.00000000000676. 2016
Telemedicine in the treatment of patients with inflammatory bowel disease
Review. 10.1016/j.gastrohep.2017.07.001. 2017
Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.
Del Hoyo J; (...); Aguas M
Article. 10.2196/15505. 2019
Telemonitoring with TECCU of active Inflammatory Bowel Disease is Not Inferior to Standard Care: Short-term Results of a Multicentre Randomized Controlled Trial of GETECCU.
Article. 10.2196/60966. 2024
Terapia de rescate con ciclosporina oral tras el uso de ustekinumab en colitis ulcerosa resistente a múltiples tratamientos.
Abia PL; (...); Niclós BB
Letter. 10.1016/j.gastrohep.2021.04.012. 2021
The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry
Guasch, M; (...); Domenech, E
Meeting Abstract. 2018
The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
Ladron Abia, Pablo; (...); Iborra, Marisa
Article. 10.1016/j.gastrohep.2022.01.004. 2022
The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study.
Gutierrez-Ontalvilla, P.; (...); Iborra, M.
Article. 10.1007/s00266-021-02718-1. 2022
The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions.
Zabana Y; (...); Domènech E
Article. 10.1016/j.gastrohep.2020.05.007. 2020
The Female Sexual Function Index to assess patients with moderate to severe vulvar lichen sclerosus.
Gutierrez-Ontalvilla P; (...); Vicente D
Letter. 10.1684/ejd.2019.3580. 2019
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study.
Echarri A; (...); Muñiz J
Article. 10.1089/tmj.2018.0264. 2020
The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 2018
The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making
Bastida Paz, Guillermo; (...); Nos, Pilar
Article. 10.1159/000531789. 2023
Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response
Minguez, A.; (...); Nos, P.
Meeting Abstract. 2023
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Rodríguez-Moranta F; (...); Gutiérrez Casbas A
Practice Guideline. 10.1016/j.gastrohep.2024.01.007. 2024
Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
Ferreiro Iglesias, R.; (...); Barreiro-de Acosta, M.
Meeting Abstract. 2022
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; (...); Gisbert JP
Article. 10.1093/ecco-jcc/jjaa145. 2021
-
-
PlumX Metrics
- Citations
- Citation Indexes: 79
- Policy Citations: 1
- Captures
- Readers: 122
- Mentions
- News Mentions: 1
TREATMENT OF IRON DEFICIENCY WITHOUT ANEMIA WITH FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PROSPECTIVE EVALUATION OF CLINICAL AND PATIENT-REPORTED OUTCOMES IN SPAIN
Huguet, J. M.; (...); Munoz, M.
Meeting Abstract. 2022
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: Results from the VERNE study.
Bastida G; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2021.06.005. 2021
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
Gomez-Labrador, Celia; (...); Gisbert, Javier P
Article. 10.3390/pharmaceutics16050629. 2024
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU.
Mesonero F; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2024.09.023. 2024
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Urine metabolome profiling of immune-mediated inflammatory diseases
Alonso, A; (...); IMID Consortium
Article. 10.1186/s12916-016-0681-8. 2016
Use of Magnetic Resonance Index of Activity (MaRIA) in the preoperative assessment of small bowel Crohn's disease.
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1016/j.ciresp.2019.06.018. 2019
Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
Camba, AH; (...); Ramos, L
Meeting Abstract. 2020
Use of telemedicine in inflammatory bowel disease: a real monitoring option?
Editorial Material. 10.1080/17474124.2016.1200464. 2016
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
Chaparro, M; (...); Gisbert, JP
Article. 10.1097/MEG.0000000000001706. 2020
Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Sard, M. Calafat; (...); Domenech, E.
Meeting Abstract. 2023
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
Manosa, Miriam; (...); Domenech, Eugeni
Article. 10.1016/j.dld.2022.07.013. 2022
Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2022
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
Khorrami, S; (...); Gisbert, JP
Article. 10.1097/MIB.0000000000000842. 2016
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 153
- Patent Family Citations: 1
- Policy Citations: 2
- Captures
- Readers: 155
- Mentions
- News Mentions: 1
Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients
Mateos, B.; (...); Beltran, B.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021
Variability in Mesalazine Management for Ulcerative Proctitis Include Doses, Route of Administration and Use of Fecal Calprotectin: Insights from Clinical Practice Across Spain Beyond Clinical Guidelines
Bastida Paz, G.; (...); Gonzalez-Lama, Y.
Meeting Abstract. 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens, Geert; (...); Laharie, David
Article. 10.1016/S2468-1253(24)00317-0. 2025
Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
Meeting Abstract. 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Article. 10.1016/j.gastrohep.2018.06.001. 2018
Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse
Article. 10.1007/s10620-018-5429-1. 2019